Abstract: This invention relates to the use of promoters for ribonucleic acid amplification and other genetic manipulations. Processes are provided wherein complementary deoxyribonucleic acid (cDNA) is synthesized from a ribonucleic acid (RNA) sequence using a complementary primer linked to an RNA polymerase promoter region complement and then anti-sense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region. Additional processes using the resulting aRNA are also described.

Abstract: This invention relates to the use of promoters for ribonucleic acid amplification and other genetic manipulations. Processes are provided wherein complementary deoxyribonucleic acid (cDNA) is synthesized from a ribonucleic acid (RNA) sequence using a complementary primer linked to an RNA polymerase promoter region complement and then anti-sense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region. Additional processes using the resulting aRNA are also described.

Abstract: This invention relates to the use of promoters for ribonucleic acid amplification and other genetic manipulations. Processes are provided wherein complementary deoxyribonucleic acid (cDNA) is synthesized from a ribonucleic acid (RNA) sequence using a complementary primer linked to an RNA polymerase promoter region complement and then anti-sense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region. Additional processes using the resulting aRNA are also described.

Abstract: This invention relates to the use of promoters for ribonucleic acid amplification and other genetic manipulations. Processes are provided wherein complementary deoxyribonucleic acid (cDNA) is synthesized from a ribonucleic acid (RNA) sequence using a complementary primer linked to an RNA polymerase promoter region complement and then anti-sense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region. Additional processes using the resulting aRNA are also described.

Abstract: This invention relates to the use of promoters for ribonucleic acid amplification and other genetic manipulations. Processes are provided wherein complementary deoxyribonucleic acid (cDNA) is synthesized from a ribonucleic acid (RNA) sequence using a complementary primer linked to an RNA polymerase promoter region complement and then anti-sense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region. Additional processes using the resulting aRNA are also described.

Abstract: Compounds of formula I are useful for suppressing appetite, and for altering macronutrient preferences, ##STR1## where the R.sub.2 -R.sub.9 substituents are so selected as to meet a defined quantitative structure activity relationship (QSAR) quantity relating to the partition coefficient of the compound, the net charge on the ring nitrogen, and the radical superfdelocalizability at the position-8 ring carbon.

Abstract: In situ transcription is provided by hybridizing cells or tissue with a primer, and extending the primer bound to any template mRNA or DNA with transverse transcriptase or DNA polymerase in the presence of labeled nucleotides, which allows for detection of cells containing the template. The resulting cDNA may be eluted and used in a polymerase chain reaction for isolation of the DNA, and/or the cDNA electrophoresed, which may provide for information concerning the sequence, or the like.

Abstract: In situ transcription is provided by hybridizing cells or tissue with a primer, and extending the primer bound to any template mRNA or DNA with reverse transcriptase or DNA polymerase in the presence of labeled nucleotides, which allows for detection of cells containing the template. The resulting cDNA may be eluted and used in a polymerase chain reaction for isolation of the DNA, and/or the cDNA electrophoresed, which may provide for information concerning the sequence, or the like.

Abstract: Compounds of formula I are useful for suppressing appetite, for altering macronutrient preferences, for suppressing obsessive-compulsive behavior, and for inhibiting cravings and substance abuse: ##STR1## wherein R.sub.1 and R.sub.3 are each independently H, hydroxy-alkyl, alpha-cyanoalkyl, SO.sub.3 H, SO.sub.2 NH.sub.2, or C(O)R, where R is OH, NH.sub.2, lower alkoxy, benzyloxy, or aliphatic amino acyl;R.sub.2 and R.sub.9 are each independently H, lower alkyl, benzyl, succinyl, or C(O)R.sub.4, where R.sub.4 is H, lower alkyl, hydrocarboxy-lower alkylene, or lower alkoxycarboxy-lower alkylene; andR.sub.5, R.sub.6, R.sub.7, and R.sub.8 are each independently H, halo, lower alkyl, hydroxy, lower alkoxy, or two adjacent radicals form methylenedioxy or ethylenedioxy;with the proviso that R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, and R.sub.9 are not simultaneously H.

Abstract: Novel peptides having gastrin releasing peptide-like activity having the structures Ala-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr-Val-Leu-Ala-Lys-Met-Tyr-Pro-NH.sub.2 and Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH.sub.2, have been isolated from rat and guinea pig brain extracts and synthesized by a solid phase peptide synthesis methods. The GRP-like peptides are useful as pharmaceuticals to lower body temperature, increase respiratory activity, reduce food intake, stimulate pancreatic hormone release, stimulate pituitary hormone release and suppress thyroid hormone release in mammals.

Abstract: A method is provided for elevating blood pressure in mammals comprising the step of administering a polypeptide containing the C-terminal residue L-Arg-L-Phe or C-terminal esters or amides thereof.

Abstract: A morphine-like amidated opioid octapeptide metorphamide having the struce Try-Gly-Gly-Phe-Met-Arg-Arg-Val-NH.sub.2 has been isolated from bovine caudate nucleus extracts and synthesized by solid phase peptide synthesis methods. Metorphamide is thus far the only natural opioid peptide having a high .mu.-binding activity.